THE NEUROPATHIC COMPONENT OF PAIN SYNDROME IN OSTEOARTHRITIS
https://doi.org/10.51523/2708-6011.2018-15-3-2
Abstract
Objective: to access (according to data of literature references) mechanisms of development of neuropathic pain in osteoarthritis and methods of its management. Material and methods. Analysis of publications containing information on neuropathic pain in osteoarthritis which are stored on the PubMed resource and the Russian information portal eLIBRARU.RU. Results. The pathogenesis of neuropathic pain of various localization in osteoarthritis has been determined, methods of its treatment have been studied. Conclusion. The work draws an inference that it is requisite to develop a more thorough approach to the treatment of pain in osteoarthritis and assessment of its effectiveness and safety.
References
1. Suri S, Gill SE, de Camin SM, Wilson D, McWilliams DF, Walsh DA. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann Rheum Dis. 2007;66(11):1423-28. doi: 10.1136/ard.2006.063354.
2. Филатова ЕС. Применение антиконвульсанта прегабалина в практике ревматолога: терапия остеоартрита коленных суставов. Рус Мед Журн. 2017; 25:1893-97.
3. Лихачев СА, Усова НН, Савостин АП, Линков МВ. Синдром центральной сенситизации. Мед Новости, 2018;1(280):19-23.
4. Eitner A, Pester J, Nietzsche S, Hofmann G O, Schaible HG. The innervation of synovium of human osteoarthritic joints in comparison with normal rat and sheep synovium. Osteoarthritis Cartilage. 2013;21(9):1383-91. doi: 10.1016 / j.joca.2013.06.018.
5. Sharma L, Pai Y C, Holtkamp K, Rymer WZ. Is knee joint proprioception worse in the arthritic knee versus the unaffected knee in unilateral knee osteoarthritis? Arthritis Rheum. 1997;40(8):1518-25. doi: 10.1002/1529-0131(199708)40:8<1518::AID-ART22>3.0.CO;2-O.
6. Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: Prevalence, sensory qualities, and postoperative determinants. Pain. 2011;152(3):566-72. doi: 10.1016 / j.pain.2010.11.023.
7. Moulin DE, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Man. 2014;19(6):328-35. PMCID: PMC4273712.
8. McNamee KE, Burleigh A, Gompels LL, Feldmann M, Allen SJ, Williams RO, Dawbarn D, Vincent TL, Inglis JJ. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain 2010;149:386-92. doi: 10.1016/j.pain.2010.03.002.
9. Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J Bone Miner Res. 2007;22:1732-42. doi: 10.1359/jbmr.070711.
10. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521-31. doi: 10.1056/NEJMoa0901510.
Review
For citations:
Savarina V.A. THE NEUROPATHIC COMPONENT OF PAIN SYNDROME IN OSTEOARTHRITIS. Health and Ecology Issues. 2018;(3):8-11. (In Russ.) https://doi.org/10.51523/2708-6011.2018-15-3-2
Views: 308
Email this article 